Amplia’s CEO and Managing Director, Dr John Lambert, has penned an article for respected business and finance website, Switzer Daily, outlining the Company’s plans to start a Phase 2 clinical trial for AMP945 to tackle pancreatic cancer.
In Dr Lambert’s words:
“AMP945 represents a new generation of more gentle and effective cancer treatments. So far it has a very clean safety profile, which has positive implications for Amplia’s clinical development program. Having surmounted the first hurdle of clinical development, a Phase 2 clinical trial is being planned in newly diagnosed patients with pancreatic cancer as a first line therapy, in conjunction with the standard-of-care treatment. This means it will be easier to recruit healthier patients, who are more likely to respond to treatment. If successful, this could become a game-changing standard treatment following a diagnosis of pancreatic cancer.”
Read the article.
